Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,133.02 -6.24 -0.20%
FTSE 100 6,572.20 -11.97 -0.18%
DAX 9,301.16 -16.66 -0.18%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,712.85 16.84 0.07%

NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing

NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular

PR Newswire

FT. MYERS, Fla., July 25, 2013

FT. MYERS, Fla., July 25, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ:
NEO), a leading provider of cancer-focused genetic testing services, announced
today that it has validated and launched a number of clinical molecular tests
for the comprehensive profiling of myelodysplastic syndrome (MDS). 

MDS is a highly complex and difficult to diagnose disease with a wide variety
of clinical behaviors.  Management of the disease can vary significantly
depending on the severity of the disease.   NeoGenomics' comprehensive MDS
testing covers all of the known relevant molecular mutations associated with
the disease^(1)(2). NeoGenomics now provides mutation analysis of the
following genes, either individually or as a group:  SF3B1, U2AF1, SRSF2,
ZRSR2, RUNX1, EZH2, ASXL1, TET2, TP53, NRAS, CBL, PTPN11, IDH1/2 and ETV6.
NeoGenomics comprehensive MDS tests can be used for confirming diagnosis,
predicting prognosis, determining therapeutic strategy and monitoring

Doug VanOort, the company's Chairman and CEO, said "NeoGenomics is committed
to being the leading laboratory in the rapidly evolving field of molecular
pathology and now offers the most extensive menu of molecular testing services
targeted to cancer in the United States. We believe that full characterization
of cancer at the genomic level is essential in the current practice of
precision medicine"

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of
Research and Development, commented, "MDS is a heterogeneous disease and
defining the specific molecular abnormalities that drive the disease in each
specific patient is essential. NeoGenomics' MDS tests can provide profound
insights into the disease and guide treating physicians in designing the
proper personalized therapeutic strategy for individual patients." 

MDS is diagnosed in more than 10,000 people in the United States annually with
an approximate incidence rate of 4.5 cases per 100,000 people. MDS is a
myeloid malignancy characterized by peripheral blood cytopenias. The disease
can arise de novo or after exposure to chemicals, chemotherapy or radiation
therapy for other cancers. Establishing diagnosis can be very difficult and
the presentation of MDS can overlap with multiple other reactive processes.

About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that
specializes in cancer genetics testing, the fastest growing segment of the
laboratory industry. The company's testing services include cytogenetics,
fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, morphology studies, anatomic pathology and molecular
genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services
the needs of pathologists, oncologists, urologists and other clinicians, and
hospitals throughout the United States. For additional information about
NeoGenomics, visit 

Forward Looking Statements
Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements. Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.

Scientific References:

(1) Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G,
Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point
mutations in myelodysplastic syndromes.  N Engl J Med. 2011 Jun

(2) Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A,
Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV,
Maciejewski JP. Mutations in the spliceosome machinery, a novel and ubiquitous
pathway in leukemogenesis. Blood. 2012 Apr 5;119(14):3203-10.

SOURCE NeoGenomics, Inc.

Contact: NeoGenomics, Inc., Steven C. Jones, Director of Investor Relations,
(239) 325-2001,; Hawk Associates, Inc., Ms. Julie
Marshall, (305) 451-1888,
Sponsored Links
Sponsored Links